Singh, Awadhesh Kumar; Singh, Ritu published the artcile< Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs>, Application In Synthesis of 96829-58-2, the main research area is meta analysis obesity orlistat phentermine lorcaserin topiramate naltrexone pharmacotherapy; Obesity; anti-obesity drugs; liraglutide 3.0 mg; lorcaserin; naltrexone plus bupropion; orlistat; phentermine plus topiramate.
Meta-anal. of obesity poses a significant increase in morbidity and mortality and thus five anti-obesity drugs have been approved currently by US FDA. Several phase 3 trials have shown a significant improvement in cardio-metabolic profile including significant weight reduction with these agents compared to placebo. We systematically searched the database of PubMed, Embase, The Cochrane Library and The ClinicalTrials.gov up to 30 Sept. 2019 and retrieved all the randomized controlled trials (RCTs) that were conducted with these five drugs for ≥1 yr and explicitly reported their efficacy vs. placebo. Subsequently, we have conducted the meta-anal. to primarily study the effect of these anti-obesity drugs on weight reduction We addnl. reviewed the effect of these drugs on other cardio-metabolic parameters including key adverse events. This meta-anal. finds a significant reduction in body weight with orlistat (N = 10,435; Δ -3.07 Kg, 95% CI, -3.76 to -2.37), phentermine plus topiramate (N = 2985; Δ -9.77 Kg; 95% CI, -11.73 to -7.81), lorcaserin (N = 16,856; Δ -3.08 Kg; 95% CI, -3.49 to -2.66), naltrexone plus bupropion (N = 3239; Δ -4.39 Kg; 95% CI, -5.05 to -3.72) and liraglutide (N = 4978; Δ -5.25 Kg; 95% CI, -6.17 to -4.32), compared to placebo (all p < 0.00001). Expert Review of Clinical Pharmacology published new progress about Antiobesity agents. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Application In Synthesis of 96829-58-2.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics